Table 4.
Univariate and multivariate proportional hazard analyses of PSA relapse (n = 800).
| Variable | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% index | p value | Hazard ratio | 95% index | p value | |
| Serum PSA level (ng/mL) (≥7.9 vs. <7.9) | 1.6 | 1.1–2.4 | <0.001 | |||
| Gleason score (≥8 vs. ≤7) | 2.1 | 1.4–3.1 | 0.009 | - | - | - |
| Extra prostatic extension (1 vs. 0) | 2.3 | 1.6–3.6 | <0.001 | - | - | - |
| Lymphovascular invasion (1 vs. 0) | 1.4 | 1.2–2.5 | 0.006 | 1.5 | 0.8–1.7 | 0.053 |
| Perineural invasion (1 vs. 0) | 1.8 | 1.2–2.9 | <0.001 | 1.6 | 1.4–2.2 | 0.001 |
| Surgical margin (1 vs. 0) | 2.6 | 2.1–4.3 | <0.001 | 1.7 | 1.4-2.5 | 0.002 |
| Lymph node metastasis (1 vs.0) | 3.1 | 1.1–7.1 | <0.001 | - | - | - |
| RARP vs LRP | 0.8 | 0.3–1.2 | 0.004 | 0.8 | 0.3-0.9 | 0.014 |
LRP, laparoscopic radical prostatectomy; RARP, robot-assisted radical prostatectomy; PSA, prostate-specific antigen.